Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/complementary-pharmacokinetic-profiles-of-netupitant-and-palonosetron-S68NhVKuIg
References (46)
-
S. Calcagnile, C. Lanzarotti, G. Rossi, A. Henriksson, K. Kammerer, W. Timmer (2013)
Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptivesSupportive Care in Cancer, 21
-
K. Youdim, Aref Zayed, M. Dickins, A. Phipps, M. Griffiths, A. Darekar, R. Hyland, O. Fahmi, S. Hurst, D. Plowchalk, J. Cook, F. Guo, R. Obach (2008)
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.British journal of clinical pharmacology, 65 5
-
M. Stathis, C. Pietra, C. Rojas, B. Slusher (2012)
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.European journal of pharmacology, 689 1-3
-
M. Fromer (2005)
Chemotherapy-induced nausea and vomitingOncology Times UK, 2
-
C. Girish, S. Manikandan (2007)
Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting.Indian journal of cancer, 44 1
-
R. Stoltz, S. Parisi, Ajit Shah, A. Macciocchi (2004)
Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteersBiopharmaceutics & Drug Disposition, 25
-
F. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R. Gralla, E. Bruera, R. Clark-Snow, L. Dupuis, L. Einhorn, P. Feyer, P. Hesketh, K. Jordan, I. Olver, B. Rapoport, J. Roscoe, C. Ruhlmann, D. Walsh, D. Warr, M. Wetering (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 27 suppl 5
-
P. Hesketh, K. Bohlke, M. Kris (2016)
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.Journal of oncology practice / American Society of Clinical Oncology, 12 1
-
S. Shugarts, L. Benet (2009)
The Role of Transporters in the Pharmacokinetics of Orally Administered DrugsPharmaceutical Research, 26
-
V. Lorusso (2016)
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronTherapeutics and Clinical Risk Management, 12
-
S. Grunberg, D. Chua, A. Maru, J. Dinis, S. Devandry, J. Boice, J. Hardwick, E. Beckford, Arlene Taylor, A. Carides, F. Roila, J. Herrstedt (2011)
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 11
-
T. Spinelli, S. Calcagnile, C. Giuliano, G. Rossi, C. Lanzarotti, S. Mair, L. Stevens, I. Nisbet (2013)
Netupitant PET imaging and ADME studies in humansJournal of Clinical Pharmacology, 54
-
Brigitte Bloechl-Daum, R. Deuson, P. Mavros, M. Hansen, J. Herrstedt (2006)
Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 27
-
(2015)
Association between NK1 receptor occupancy (RO) of netupitant (NETU) and efficacy of NEPA, the fixed antiemetic combination of NETU and palonosetron (PALO) -
R. Navari (2013)
Management of Chemotherapy-Induced Nausea and VomitingDrugs, 73
-
(2018)
(netupitant and palonosetron) [FDA prescribing information] -
Guidance for industry: bioanalytical method validation -
C. Giuliano, E. Lovati, C. Funk, M. Potthast, C. Pietra (2012)
In Vitro Drug-Drug Interaction Studies with the Antiemetic Drug Netupitant and its Major Metabolites M1 and M2, Involving Several Human Cytochrome P450 IsoenzymesAnnals of Oncology, 23
-
D. Pfister, K. Ang, D. Brizel (2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology -
R. Navari (2010)
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.Future oncology, 6 7
-
P. Eisenberg, F. Mackintosh, P. Ritch, P. Cornett, A. Macciocchi (2004)
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.Annals of oncology : official journal of the European Society for Medical Oncology, 15 2
-
(2015)
Neurokinin-1 (NK1) receptor occupancy (RO) of netupitant in different brain regions: positron emission tomography (PET) study in healthy male subjects -
P. Hesketh, M. Kris, E. Basch, K. Bohlke, S. Barbour, Rebecca Anne, M. Danso, K. Dennis, L. Dupuis, S. Dusetzina, C. Eng, P. Feyer, K. Jordan, Kimberly Noonan, D. Sparacio, Mark eld, G. Lyman (2017)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 28
-
M. Lesurtel, Christopher Soll, Rolf Graf, P. Clavien (2008)
Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectivesCellular and Molecular Life Sciences, 65
-
G. Masters, David Johnson, S. Temin (2016)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.Journal of oncology practice / American Society of Clinical Oncology, 12 1
-
V. Lorusso, M. Karthaus, M. Aapro (2015)
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.Future oncology, 11 4
-
R. Gralla, S. Bošnjak, A. Hontsa, C. Balser, G. Rizzi, G. Rossi, M. Borroni, K. Jordan (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 25 7
-
P. Hesketh, G. Rossi, G. Rizzi, M. Palmas, A. Alyasova, I. Bondarenko, A. Lisyanskaya, R. Gralla (2014)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.Annals of oncology : official journal of the European Society for Medical Oncology, 25 7
-
(2015)
Receptor occupancy (RO) of the neurokinin-1 (NK1) receptor antagonist, netupitant, in different brain regions and relationship to antiemetic efficacy -
(2016)
Australian public assessment report for netupitant/palonosetron (as hydrochloride) -
R. Navari (2014)
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)Drug Design, Development and Therapy, 9
-
Governor, Kody Kinsley, Secretary, Mark Payne (2020)
Health and Human ServicesCongress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses
-
K. Ruddy, E. Mayer, A. Partridge (2009)
Patient adherence and persistence with oral anticancer treatmentCA: A Cancer Journal for Clinicians, 59
-
S. Calcagnile, C. Lanzarotti, M. Gutacker, Verena Jakob-Rodamer, Klaus Kammerer, W. Timmer (2015)
Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open‐label, crossover phase 1 studyClinical Pharmacology in Drug Development, 4
-
M. Bergström, R. Hargreaves, H. Burns, M. Goldberg, D. Sciberras, S. Reines, K. Petty, Mattias Ögren, G. Antoni, B. Långström, O. Eskola, M. Scheinin, O. Solin, A. Majumdar, M. Constanzer, W. Battisti, T. Bradstreet, C. Gargano, J. Hietala (2004)
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitantBiological Psychiatry, 55
-
P. Hesketh (2008)
Chemotherapy-induced nausea and vomiting.The New England journal of medicine, 358 23
-
J. Natale, T. Spinelli, S. Calcagnile, C. Lanzarotti, G. Rossi, D. Cox, Kimia Kashef (2015)
Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataJournal of Oncology Pharmacy Practice, 22
-
(2015)
Helsinn Birex Pharmaceuticals -
P. Hesketh, K. Bohlke, G. Lyman, E. Basch, Maurice Chesney, R. Clark-Snow, M. Danso, K. Jordan, M. Somerfield, M. Kris (2016)
Antiemetics: American Society of Clinical Oncology Focused Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 4
-
(2007)
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION -
P. Hesketh, S. Belle, M. Aapro, F. Tattersall, R. Naylor, R. Hargreaves, A. Carides, Judith Evans, K. Horgan (2003)
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.European journal of cancer, 39 8
-
(2014)
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines -
(2015)
Akynzeo R 300 mg/0.5 mg hard capsules. Summary of product characteristics -
F. Roila, C. Ripamonti, A. Antonuzzo, P. Bossi (2014)
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in OncologySupportive Care in Cancer, 23
-
A. Thomas, M. Stathis, C. Rojas, B. Slusher (2014)
Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cellsExperimental Brain Research, 232
-
M. Aapro, H. Rugo, G. Rossi, G. Rizzi, M. Borroni, I. Bondarenko, T. Sarosiek, C. Oprean, S. Cardona-Huerta, V. Lorusso, M. Karthaus, L. Schwartzberg, S. Grunberg (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapyAnnals of Oncology, 25
- Publisher
- Wiley
- Copyright
- © 2019, The American College of Clinical Pharmacology
- eISSN
- 1552-4604
- DOI
- 10.1002/jcph.1338
- Publisher site
- See Article on Publisher Site
Abstract
Journal
The Journal of Clinical Pharmacology – Wiley
Published: Apr 1, 2019
Keywords: ; ; ;